CClinicalTrials.gg
Status unknownNCT02866266Updated Oct 5, 2016

ER/LA Opioid Surveillance for Emergency Department Visits and Hospitalizations for Overdose and Poisoning

An observational study in Opioid-related Disorders, Opioid Addiction and Narcotic Abuse, sponsored by ER/LA Opioid REMS Program Companies (RPC). Status unknown. Per ClinicalTrials.gov, last updated 2016-10-05.

Sponsored by ER/LA Opioid REMS Program Companies (RPC) · Observational

The sponsor has not verified this record recently (last verified Oct 2016), so the status shown — last known as Active, not recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
183,452
Sex
All
01

Study summary

Study to evaluate the impact of the ER/LA opioid REMS program on the incidence of Emergency Department visits and hospitalizations for overdose/poisoning and death among patients prescribed ER/LA opioid analgesics.

Read the detailed description

As part of the FDA-approved plan to evaluate the effects of the REMS program, the REMS Program Companies (RPC) are required to submit FDA assessment reports on a regular basis. The present study is one of several program evaluation components carried out in support Assessment 5: Surveillance monitoring for misuse, abuse, overdose, addiction, death and intervention taken. This study will evaluate the impact of the ER/LA opioid REMS program on the incidence of ED visits and hospitalizations for overdose/poisoning and death among patients prescribed ER/LA opioid analgesics.

02

Conditions studied

  • Opioid-related Disorders
  • Opioid Addiction
  • Narcotic Abuse
  • Drug Abuse
03

In context

Poisoning

209 studies on the registry are indexed under Poisoning; 26 are open to participants now.

This study's enrollment of 183,452 is above the median of 121 across 94 observational studies indexed under Poisoning.

Browse Poisoning studies →

Lead sponsor

ER/LA Opioid REMS Program Companies (RPC) is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients that receive at least one dispensing of an ER/LA opioid during at least one study REMS period with at least six months of prior continuous health plan eligibility in the main analyses. Additional analyses will consider patients enrolled in the HIRD or a participating Medicaid plan regardless of ER/LA opioid exposure.

Inclusion criteria

  1. At least one dispensing of an ER/LA opioid after 01 July 2010
  2. At least six months of continuous health plan eligibility prior to the first recorded dispensing of an opioid that occurs during an included REMS period

Exclusion criteria

Exclusion Criteria:

  1. Missing or implausible values for age
  2. Missing or implausible values for gender
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
183,452 participants (actual)
Patient registry
No

Groups and cohorts

  • All commercially insured patients in the HIRD

    Other: Retrospective database review

  • All Medicaid patients in a participating state Medicaid plan

    Other: Retrospective database review

Interventions

  • OtherRetrospective database review
06

What researchers measure

Primary outcomes

  1. Number of ED visits for opioid overdose/poisoning and mortality

    Time frame: Retrospective review over period from July 2010 through December 2014

  2. Number of hospitalizations for opioid overdose/poisoning and mortality

    Time frame: Retrospective review over period from July 2010 through December 2014

Secondary outcomes

  1. All-cause mortality

    Time frame: Retrospective review over period from July 2010 through December 2014

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 5, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02866266
Lead sponsor
ER/LA Opioid REMS Program Companies (RPC)
Collaborators
HealthCore, Inc.
Responsible party
Sponsor
First posted
Aug 15, 2016
Primary completion
Oct 2015
Last update
Oct 5, 2016
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion